Guido Marcucci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9619401/publications.pdf

Version: 2024-02-01

167 papers	9,290 citations	76196 40 h-index	40881 93 g-index
168 all docs	168 docs citations	168 times ranked	10863 citing authors

#	Article	IF	Citations
1	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation. New England Journal of Medicine, 2017, 377, 454-464.	13.9	1,628
2	IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 2348-2355.	0.8	699
3	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 2008, 111, 3183-3189.	0.6	575
4	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine, 2008, 358, 1919-1928.	13.9	427
5	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 5705-5717.	0.8	324
6	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 721-749.	2.3	314
7	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 5078-5087.	0.8	294
8	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood, 2019, 133, 1548-1559.	0.6	292
9	The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood, 2011, 117, 1121-1129.	0.6	247
10	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 2008, 111, 1552-1559.	0.6	243
11	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	9.4	231
12	Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 9234-9242.	0.8	226
13	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 2003, 101, 425-432.	0.6	221
14	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica, 2018, 103, e404-e407.	1.7	212
15	High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2007, 25, 3337-3343.	0.8	184
16	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology, 2013, 31, 2086-2093.	0.8	165
17	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	0.6	127
18	Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 858-865.	2.0	126

#	Article	IF	Citations
19	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine, 2018, 24, 450-462.	15.2	123
20	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell, 2016, 30, 764-778.	7.7	116
21	Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Current Opinion in Hematology, 2005, 12, 68-75.	1.2	110
22	Myeloid cellâ€“targeted miR-146a mimic inhibits NF-ÎºBâ€“driven inflammation and leukemia progression in vivo. Blood, 2020, 135, 167-180.	0.6	88
23	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 618-624.	2.0	84
24	Decitabine enhances anti-CD33 monoclonal antibody BI 836858â€“mediated natural killer ADCC against AML blasts. Blood, 2016, 127, 2879-2889.	0.6	80
25	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	7.7	79
26	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	3.3	76
27	HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation. Cell Stem Cell, 2015, 17, 597-610.	5.2	75
28	Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood, 2012, 120, 1130-1136.	0.6	74
29	Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood, 2016, 127, 1687-1700.	0.6	70
30	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood, 2021, 137, 471-484.	0.6	70
31	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell, 2018, 23, 355-369.e9.	5.2	68
32	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplantation and Cellular Therapy, 2021, 27, 938.e1-938.e6.	0.6	63
33	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. American Journal of Hematology, 2019, 94, E253-E255.	2.0	62
34	PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia. Blood, 2019, 134, 548-560.	0.6	58
35	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	3.3	51
36	The Bclâ€2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. Journal of Cellular Physiology, 2019, 234, 14040-14049.	2.0	50

#	Article	IF	Citations
37	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 2014, 13, 1979-1990.	1.9	49
38	Venetoclax and hypomethylating agents in TP53â€mutated acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e45-e48.	1.2	49
39	Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. American Journal of Hematology, 2019, 94, 358-362.	2.0	46
40	MicroRNA expression in acute myeloid leukemia. Current Hematologic Malignancy Reports, 2009, 4, 83-88.	1.2	44
41	HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. Blood, 2017, 130, 2619-2630.	0.6	41
42	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica, 2018, 103, 1662-1668.	1.7	41
43	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	2.5	34
44	MiR-16 regulates crosstalk in NF-ÎºB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	2.3	33
45	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. Blood, 2019, 134, 432-444.	0.6	32
46	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, e322-e327.	2.0	32
47	Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights. Oncology, 2016, 30, 318-29.	0.4	31
48	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. Blood, 2019, 134, 1257-1268.	0.6	30
49	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	30
50	Venetoclax and hypomethylating agents in <scp>FLT3</scp>â€mutated acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1193-1199.	2.0	28
51	Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Clinical Cancer Research, 2003, 9, 1248-52.	3.2	28
52	Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nature Communications, 2021, 12, 6154.	5.8	27
53	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. Best Practice and Research in Clinical Haematology, 2009, 22, 239-248.	0.7	26
54	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica, 2017, 102, 2030-2038.	1.7	26

#	Article	IF	Citations
55	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. Cancer Research, 2020, 80, 3157-3169.	0.4	25
56	Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. Journal of Hematology and Oncology, 2021, 14, 70.	6.9	25
57	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	2.5	25
58	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.2	23
59	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. Leukemia Research, 2017, 59, 124-135.	0.4	22
60	ILC1s control leukemia stem cell fate and limit development of AML. Nature Immunology, 2022, 23, 718-730.	7.0	22
61	CBFÎ²-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice. Blood, 2016, 128, 1503-1515.	0.6	21
62	The role of ErbB3 binding protein 1 in cancer: Friend or foe?. Journal of Cellular Physiology, 2018, 233, 9110-9120.	2.0	20
63	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1084-1090.	2.0	19
64	CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies. Blood, 2018, 132, 1408-1408.	0.6	19
65	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq1 1 0.784314 rgBT	1.3	17
66	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer, 2022, 128, 529-535.	2.0	17
67	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 2018, 103, 982-987.	1.7	16
68	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8.	0.6	16
69	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1828-1835.	2.0	15
70	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leukemia and Lymphoma, 2020, 61, 2020-2023.	0.6	15
71	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	2.5	15
72	Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Advances, 2019, 3, 1027-1032.	2.5	14

#	Article	IF	Citations
73	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. Biology of Blood and Marrow Transplantation, 2020, 26, 292-299.	2.0	13
74	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2020, 55, 877-883.	1.3	13
75	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. Journal of Hematology and Oncology, 2021, 14, 122.	6.9	13
76	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372.	0.6	13
77	Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1212-1217.	2.0	12
78	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e400-e405.	0.2	12
79	8â€chloroâ€adenosine activity in FLT3â€ITD acute myeloid leukemia. Journal of Cellular Physiology, 2019, 234, 16295-16303.	2.0	12
80	Philadelphia chromosome as a recurrent event among therapyâ€related acute leukemia. American Journal of Hematology, 2017, 92, E18-E19.	2.0	11
81	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. Bone Marrow Transplantation, 2020, 55, 473-475.	1.3	11
82	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorableâ€risk acute myeloid leukemia. American Journal of Hematology, 2021, 96, E59-E63.	2.0	11
83	A novel vitamin D gene therapy for acute myeloid leukemia. Translational Oncology, 2020, 13, 100869.	1.7	10
84	Discovery of proangiogenic CD44+mesenchymal cancer stem cells in an acute myeloid leukemia patientâ€™s bone marrow. Journal of Hematology and Oncology, 2020, 13, 63.	6.9	10
85	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia. Leukemia, 2021, 35, 2285-2298.	3.3	10
86	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<scp>HMAâ€Ven</scp>) or liposomal daunorubicinâ€cytarabine (<scp>CPX</scp>â€351). American Journal of Hematology, 2021, 96, E196-E200.	2.0	10
87	Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38â^' Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABLâ€“ independent Signals. Blood, 2008, 112, 189-189.	0.6	10
88	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. Leukemia Research, 2019, 87, 106230.	0.4	9
89	Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIFâ€90â€mediated ribosomal RNA synthesis. Journal of Cellular Physiology, 2019, 234, 17612-17621.	2.0	9
90	HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging, 2020, 12, 16759-16774.	1.4	9

#	Article	IF	Citations
91	Exosome-driven lipolysis and bone marrow niche remodeling support leukemia expansion. Haematologica, 2021, 106, 1484-1488.	1.7	9
92	Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition. Science Advances, 2022, 8, eabj1664.	4.7	9
93	Introduction: Acute Myeloid Leukemia. Seminars in Oncology, 2008, 35, 324-325.	0.8	8
94	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. Bone Marrow Transplantation, 2021, 56, 2464-2470.	1.3	8
95	Roadmap on plasticity and epigenetics in cancer. Physical Biology, 2022, 19, 031501.	0.8	8
96	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1697-1703.	2.0	6
97	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	0.7	6
98	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. Transplantation and Cellular Therapy, 2021, 27, 255.e1-255.e9.	0.6	6
99	More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine. Chinese Clinical Oncology, 2019, 8, S25-S25.	0.4	6
100	Donor derived leukemia in allogeneic transplantation. Leukemia and Lymphoma, 2021, 62, 2823-2830.	0.6	6
101	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. British Journal of Haematology, 2022, 196, .	1.2	6
102	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. Leukemia Research, 2019, 84, 106196.	0.4	5
103	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. Leukemia and Lymphoma, 2020, 61, 3532-3533.	0.6	5
104	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1425-1432.	2.0	5
105	Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia, 2022, 36, 492-506.	3.3	5
106	Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia. Blood, 2015, 126, 3802-3802.	0.6	5
107	Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism. Cancers, 2022, 14, 1446.	1.7	5
108	MicroRNA networks in FLT3-ITD acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2112482119.	3.3	5

#	Article	IF	Citations
109	Aging in a Relativistic Biological Space-Time. Frontiers in Cell and Developmental Biology, 2018, 6, 55.	1.8	4
110	Requirement of GTP binding for TIFâ€90â€regulated ribosomal RNA synthesis and oncogenic activities in human colon cancer cells. Journal of Cellular Physiology, 2020, 235, 7567-7579.	2.0	4
111	Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. Leukemia Research, 2021, 104, 106579.	0.4	4
112	Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patientsâ€™ bone marrow. Neoplasia, 2021, 23, 1252-1260.	2.3	4
113	High prevalence and inferior longâ€term outcomes for <scp>TP53</scp> mutations in therapyâ€related acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, .	2.0	4
114	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. Transplantation and Cellular Therapy, 2022, 28, 368.e1-368.e7.	0.6	4
115	Refractory primary autoimmune myelofibrosis treated with ruxolitinib. American Journal of Hematology, 2021, 96, E283-E285.	2.0	3
116	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. Blood, 2018, 132, 1552-1552.	0.6	3
117	Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality.. Blood, 2006, 108, 5515-5515.	0.6	3
118	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	0.6	3
119	Molecular markers in acute myeloid leukemia. Clinical Advances in Hematology and Oncology, 2009, 7, 448-51.	0.3	3
120	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2020, 95, 1457-1465.	2.0	2
121	Cytokine gene polymorphisms are associated with response to blinatumomab in Bâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2021, 106, 851-858.	1.1	2
122	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer Journal, 2021, 11, 125.	2.8	2
123	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). Blood, 2020, 136, 37-38.	0.6	2
124	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. Blood, 2020, 136, 49-50.	0.6	2
125	Proteomics Profiling of Leukemia Derived Exosomes: A Potential Role in Leukemic Transformation. Blood, 2015, 126, 3857-3857.	0.6	2
126	Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells. Blood, 2015, 126, 51-51.	0.6	2

#	Article	IF	Citations
127	CCND1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma. Blood, 2016, 128, 4094-4094.	0.6	2
128	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. Blood, 2016, 128, 2909-2909.	0.6	2
129	Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. Blood, 2021, 138, 3430-3430.	0.6	2
130	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation, 2021, , .	1.3	2
131	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transplantation, 2022, 57, 830-833.	1.3	2
132	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, 63, 1220-1226.	0.6	2
133	Not only TKI! Targeting FLT3-ITD by autophagy. Blood, 2016, 127, 796-797.	0.6	1
134	Rebound thrombocytosis is associated with response in <scp>AML</scp> patients treated with venetoclax and hypomethylating agents. American Journal of Hematology, 2021, 96, E140-E143.	2.0	1
135	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. Blood, 2019, 134, 4518-4518.	0.6	1
136	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. Blood, 2016, 128, 214-214.	0.6	1
137	HDAC8 Regulates Long-Term Hematopoietic Stem Cell Quiescence and Maintenance. Blood, 2016, 128, 1468-1468.	0.6	1
138	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. Blood, 2018, 132, 3416-3416.	0.6	1
139	A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 334-334.	0.6	1
140	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	0.6	1
141	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkinâ€™s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. Blood, 2008, 112, 3169-3169.	0.6	0
142	Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155. Blood, 2010, 116, 245-245.	0.6	0
143	Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprograming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1743-1743.	0.6	0
144	Philadelphia (Ph) Chromosome (BCR-ABL1 fusion) As a Recurrent Genetic Abnormality Among Therapy-Related Acute Leukemia. Blood, 2016, 128, 3974-3974.	0.6	0

#	Article	IF	Citations
145	A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2016, 128, 3547-3547.	0.6	0
146	Time Sequential Transcriptome Analysis Identifies Mir-126 As an Early Biomarker for Inv(16) Acute Myeloid Leukemia (AML) Disease Progression. Blood, 2016, 128, 773-773.	0.6	0
147	EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML). Blood, 2016, 128, 2689-2689.	0.6	0
148	8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199). Blood, 2016, 128, 2758-2758.	0.6	0
149	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. Blood, 2018, 132, 1752-1752.	0.6	0
150	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	0.6	0
151	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1549-1549.	0.6	0
152	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. Blood, 2018, 132, 3386-3386.	0.6	0
153	Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3938-3938.	0.6	0
154	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. Blood, 2018, 132, 2181-2181.	0.6	0
155	Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS). Blood, 2021, 138, 3690-3690.	0.6	0
156	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. Blood, 2021, 138, 3037-3037.	0.6	0
157	Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Predicted Novel Biomarkers for Hyper-CVAD (CVAD) Treatment Response and Combination of Rituximab and Cladribine (RC) in CVAD Resistant Cases of Mantle Cell Lymphoma (MCL). Blood, 2021, 138, 3550-3550.	0.6	0
158	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. Blood, 2021, 138, 3955-3955.	0.6	0
159	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). Blood, 2021, 138, 226-226.	0.6	0
160	Multi-Antigen Primed T Cells Promote Apoptosis of Acute Myeloid Leukemia (AML). Blood, 2021, 138, 4794-4794.	0.6	0
161	Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singulaâ„¢: Mycare-020-02. Blood, 2020, 136, 9-10.	0.6	0
162	Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia. Blood, 2020, 136, 39-39.	0.6	0

#	Article	IF	Citations
163	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. Blood, 2020, 136, 21-22.	0.6	0
164	Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singulaâ„¢: Mycare-020-01. Blood, 2020, 136, 35-35.	0.6	0
165	Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC). Blood, 2020, 136, 4-4.	0.6	0
166	Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia. Blood, 2020, 136, 26-26.	0.6	0
167	Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo. Blood, 2020, 136, 22-23.	0.6	0